Non Hodgkin Lymphoma Clinical Trial

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Summary

This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk diffuse large B-cell lymphoma (DLBCL). Induction treatment with R-CHOP (± lenalidomide) will last for a total of up to 6 to 8 treatment cycles (21 day cycles), and the total time on study treatment, including durvalumab consolidation, will last up to 12 months.

On 05-Sep-2017, the US FDA has issued a Partial Clinical Hold on this study resulting in the discontinuation of enrollment into Arm B (Durvalumab + Lenalidomide + R-CHOP). After the US FDA Partial Clinical Hold, new eligible participants have been enrolled in Arm A (Durvalumab + R-CHOP).

View Full Description

Full Description

This research study is conducted in participants with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Patients with high-risk DLBCL typically have insufficient therapeutic outcomes. Therefore, the addition of novel agents to the currently used induction therapy (R-CHOP) is a rational approach to improve therapeutic outcomes in this disease setting.

Based on pre-clinical and clinical observations, it is hypothesized that durvalumab will have activity in DLBCL because the PD 1/PD L1 pathway is involved in the pathophysiology of DLBCL. In particular, the addition of durvalumab may augment the anti-tumor activity of R-CHOP against high-risk DLBCL sub-types.

The safety of durvalumab has already been explored. However, as there is limited clinical experience with durvalumab in DLBCL, the study is divided into two stages:

A Safety Run-in Stage to evaluate the safety of the treatment combinations until at least 10 subjects are included in each of the two treatment arms
An Expansion Stage to analyze the clinical activity of the treatment combinations

Results posted following Primary Outcome Completion date are based on a database cut-off of August 2, 2018.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

CD20+Diffuse Large B-Cell Lymphoma.
Ann Arbor stage 3 or 4 or stage 2 with bulky disease
High or high-intermediate disease risk.
No prior anti-lymphoma treatment.
Subject is willing and able to undergo biopsy.
Investigator considers R-CHOP immunochemotherapy appropriate.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 * 10^9/L, platelet count ≥ 75 * 10^9/L, hemoglobin ≥ 10.0 g/dL).
Adequate biochemistry laboratory results (aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 * upper limit of normal; bilirubin ≤ 2.0 mg/dL; creatinine clearance of ≥ 40 mL/min).
Bi-dimensionally measurable disease (> 2.0 cm).
Subject is using effective contraception.

Exclusion Criteria:

Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.
Composite lymphoma or transformed lymphoma.
Primary or secondary Central Nervous System involvement by lymphoma.
Seropositive or active viral infection with hepatitis B virus, human immunodeficiency virus or hepatitis C virus.
History of other malignancies, unless disease-free for ≥ 5 years.
Left ventricular ejection fraction < 50%.
Peripheral neuropathy ≥ Grade 2.
Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.
High risk of developing thromboembolic events, who are unwilling to take venous thromboembolism prophylaxis.
Active or prior documented autoimmune or inflammatory disorders within the past 3 years.
Current or prior use of immunosuppressive medication within 28 days before start of treatment.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT03003520

Recruitment Status:

Completed

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

Banner MD Anderson Cancer Center
Gilbert Arizona, 85234, United States
Parkview Research Center
Fort Wayne Indiana, 46845, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
University of Rochester Medical Center
Rochester New York, 14642, United States
Mid Ohio Oncology Hematology Inc
Columbus Ohio, 43219, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
Innsbruck Medical University Department of Internal Medicine
Innsbruck , 6020, Austria
Landeskrankenhaus Salzburg
Salzburg , 5020, Austria
Medical University of Vienna Internalmedicine 1, Hematology
Vienna , 1190, Austria
Hanusch Krankenhaus
Wien , 1140, Austria
Aarhus Sygehus
Arhus C , DK-80, Denmark
Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen
Copenhagen , 2100, Denmark
Odense Universitetshospital
Odense C , DK500, Denmark
(North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik
Tallinn , 13419, Estonia
Tartu University Hospital
Tartu , 51014, Estonia
University Hospital Birmingham
Birmingham , B15 2, United Kingdom
Royal Marsden Hospital
London , SW3 6, United Kingdom
Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine
Oxford , 0X3 7, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT03003520

Recruitment Status:

Completed

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.